Raymond James & Associates Has $1.53 Million Holdings in Surgery Partners, Inc. (NASDAQ:SGRY)

Raymond James & Associates lessened its stake in shares of Surgery Partners, Inc. (NASDAQ:SGRY) by 22.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 47,688 shares of the company’s stock after selling 13,500 shares during the period. Raymond James & Associates’ holdings in Surgery Partners were worth $1,526,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in Surgery Partners by 23.2% in the 3rd quarter. Wellington Management Group LLP now owns 8,022,700 shares of the company’s stock worth $234,664,000 after purchasing an additional 1,511,396 shares during the last quarter. Durable Capital Partners LP lifted its stake in shares of Surgery Partners by 174.3% in the fourth quarter. Durable Capital Partners LP now owns 5,853,995 shares of the company’s stock worth $163,092,000 after buying an additional 3,719,766 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Surgery Partners by 41.1% during the 2nd quarter. BlackRock Inc. now owns 5,372,530 shares of the company’s stock worth $241,710,000 after buying an additional 1,565,138 shares during the period. Clearbridge Investments LLC grew its stake in Surgery Partners by 0.8% in the 3rd quarter. Clearbridge Investments LLC now owns 5,277,909 shares of the company’s stock valued at $154,379,000 after buying an additional 41,557 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Surgery Partners by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 3,775,566 shares of the company’s stock worth $88,349,000 after acquiring an additional 22,936 shares during the period.

Analyst Ratings Changes

SGRY has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Surgery Partners from a “sell” rating to a “hold” rating in a report on Thursday, March 21st. Barclays began coverage on Surgery Partners in a research note on Wednesday, March 6th. They set an “equal weight” rating and a $35.00 target price for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $49.00 price target on shares of Surgery Partners in a research report on Thursday, February 29th. Cantor Fitzgerald reissued an “overweight” rating and issued a $43.00 price objective on shares of Surgery Partners in a research report on Wednesday, April 10th. Finally, Citigroup lowered their price objective on shares of Surgery Partners from $43.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $43.63.

Surgery Partners Price Performance

Shares of SGRY stock opened at $23.42 on Friday. Surgery Partners, Inc. has a 12 month low of $22.05 and a 12 month high of $45.79. The company has a market capitalization of $2.97 billion, a P/E ratio of -234.20, a P/E/G ratio of 2.26 and a beta of 2.71. The stock has a 50 day moving average of $29.81 and a two-hundred day moving average of $29.91. The company has a current ratio of 1.71, a quick ratio of 1.57 and a debt-to-equity ratio of 0.89.

Surgery Partners (NASDAQ:SGRY) last issued its earnings results on Monday, February 26th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. The firm had revenue of $735.40 million during the quarter, compared to analysts’ expectations of $741.93 million. Surgery Partners had a positive return on equity of 3.65% and a negative net margin of 0.43%. Surgery Partners’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same period last year, the business earned $0.22 earnings per share. As a group, equities analysts expect that Surgery Partners, Inc. will post 0.78 EPS for the current year.

Insider Buying and Selling at Surgery Partners

In other news, CEO Jason Eric Evans sold 5,780 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $35.08, for a total value of $202,762.40. Following the sale, the chief executive officer now directly owns 419,118 shares in the company, valued at approximately $14,702,659.44. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Marissa Brittenham sold 1,637 shares of the stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $31.89, for a total transaction of $52,203.93. Following the completion of the sale, the insider now owns 30,469 shares in the company, valued at approximately $971,656.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jason Eric Evans sold 5,780 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $35.08, for a total transaction of $202,762.40. Following the completion of the transaction, the chief executive officer now owns 419,118 shares in the company, valued at $14,702,659.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,774 shares of company stock valued at $608,352. 2.60% of the stock is currently owned by corporate insiders.

Surgery Partners Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.